JPRN-UMIN000003986已完成2 期
Phase II study of S-1 for non-small lung cancer after failure of two or three prior chemotherapy regimens - Phase II study of 3rd-line S-1 for NSCLC
ational Hospital Organization Asahikawa Medical Cencer0 个研究点目标入组 40 人开始时间: 2010年8月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Previous histories of drug allergy, which may increase the risk of this study. 2. Serious concomitant infection or high-grade fever exceeding 38 deg C or more. 3. Usages of oral steroids or immunosuppressive drugs. 4. Serious complications including severe cardiovascular disease, cerebrovascular disease, severe hypertension, active peptic ulcer, uncontrolled diabetes. 5. Interstitial pneumonia or pulmonary fibrosis on chest X-ray or CT scans. 6. Any prior treatments with S-1 or UFT. 7. Any coelomic fluids (pleural, pericardial, or ascites), which require emergent treatment. 8. Symptomatic brain metastases. 9. Other active multiple cancers. 10. Severe heart diseases. 11. Psychiatric conditions, which may increase the risks associated with the study participation. 12. Pregnant or nursing women. 13. Other conditions, on which the judgment of the investigator would make the patient inappropriate for entry.
研究者
相似试验
未知
不适用
S-1 as second line for non-small cell lung cancer with preexisting interstitial pneumonia: phase II study.non-small cell lung cancerJPRN-UMIN000022165Hamamatsu University School of Medicine28
招募中
2 期
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lung Cancer (NSCLC)NCT06693336ToLymph Inc.42
进行中（未招募）
不适用
A PHASE II TRIAL ON NON-SMALL-CELL LUNG CANCER STEM CELLS SENSITIVITY ASSAY (LUCAS)Histologically/cytologically confirmed diagnosis of metastatic NSCLC.Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neoplastic effusion.Performance status of 0-1 according to ECOG score.EUCTR2012-001440-22-IT
终止
1 期
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid MalignanciesSolid TumorsNCT01930292Debiopharm International SA31
尚未招募
不适用
Designing information for lung cancer patients in decision making.Patients presenting with a stage I non-small cell lung cancer (NSCLC).Patienten met stadium I niet kleincellige longkanker.NL-OMON2116225